Clinical Trials Logo
  1. Home
  2. OCD
  3. NCT00399022
  4. Details
NCT00399022 Clinical Trial

Treatment With Duloxetine for OCD Patients

OCD Clinical Trial

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT00399022
Other study ID # SHEBA-06-4360-JZ-CTIL
Secondary ID
Status Withdrawn
Phase N/A
First received November 13, 2006
Last updated January 28, 2008

Study information
Verified date January 2008
Source Sheba Medical Center
Contact n/a
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Interventional

Clinical Trial Summary

Testing the efficacy of the SNRI medication Duloxetine for treating OCD patients who did not respond to SSRI

Recruitment information / eligibility
Status Withdrawn
Enrollment 40
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- OCD as main diagnosis according to DSM-IV

- Age 18 to 65

- Men and women

- YBOCS score is 18 or more, or 12 or more in case of only obsessions

Exclusion Criteria:

- Patients treated with Duloxetine, currently or in the past

- Patients having comorbid schizophrenia or psychotic disorder or bipolar disorder Patients with substance abuse disorder in the last 6 months Patients who were suicidal or did serious suicide attempt in the last year Pregnant or lactating women, or woman of childbearing potential, which is not using adequate contraception Patients with neurologic disturbance or disorder Patients with serious or imbalanced medical condition Patients with allergic response to SSRI or duloxetine Patients who started new treatment (CBT or pharmacology) in less than 3 months

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Duloxetine

Locations
Country Name City State
Israel Chaim Sheba Medical Center Ramat-Gan

Sponsors (1)
Lead Sponsor Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

See also
  Status Clinical Trial Phase
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00215137 - Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder Phase 2
Recruiting NCT06050369 - Objective Characterizatoion of Repetitive Behaviors N/A
Recruiting NCT06347978 - Personalized DBS for OCD Guided by Stereoencephalography Mapping N/A
Withdrawn NCT03926546 - Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT05712057 - Neurostimulation Versus Therapy for Problems With Emotions N/A
Not yet recruiting NCT03313622 - Locating Biomarkers in OCD Through Behavioral Tasks
Withdrawn NCT03842345 - DELPhI Evaluation of Psychiatric Conditions
Completed NCT02866422 - Development of an Instrument That Monitors Behaviors Associated With OCD N/A
Completed NCT01833442 - Randomized Controlled Meditation Trial for Treating OCD N/A
Recruiting NCT04904952 - Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients N/A
Completed NCT05981690 - Therapist Guided, Parent-led, Cognitive Behavioural Therapy (CBT) for Preadolescent Children With Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT02500888 - Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder N/A
Recruiting NCT06244121 - Effect of Pyridoxine as Add-on Therapy in OCD Patients N/A
Recruiting NCT05580614 - Paired tVNS With ERP in OCD N/A
Active, not recruiting NCT03511534 - Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder N/A
Recruiting NCT05624528 - A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder Phase 2
Recruiting NCT05881356 - Discovering Factors in the Clinical Study Journey of Patients With OCD
Recruiting NCT05359562 - How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD N/A
Recruiting NCT03459456 - Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE)